Description:

NSABP Protocol B-40 - Treatment Form for Doxorubicin/Cyclophosphamide (All Patients) NCT00408408 A Randomized Phase III Trial of Neoadjuvant Therapy in Patients With Palpable and Operable Breast Cancer Evaluating the Effect on Pathologic Complete Response (pCR) of Adding Capecitabine or Gemcitabine to Docetaxel When Administered Before AC With or Without Bevacizumab and Correlative Science Studies Attempting to Identify Predictors of High Likelihood for pCR With Each of the Regimens Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=1B00492A-70E3-51F1-E044-0003BA3F9857

Link:

https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=1B00492A-70E3-51F1-E044-0003BA3F9857

Keywords:
Versions (3) ▾
  1. 12/18/14
  2. 1/9/15
  3. 6/16/15
Uploaded on:

June 16, 2015

DOI:
No DOI assigned. To request one please log in.
License:
Creative Commons BY-NC 3.0 Legacy
Model comments:

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for:

Item comments for:

In order to download data models you must be logged in. Please log in or register for free.

NSABP Protocol B-40 - Treatment Form for Doxorubicin/Cyclophosphamide (All Patients) NCT00408408

No Instruction available.

  1. StudyEvent: NSABP Protocol B-40 - Treatment Form for Doxorubicin/Cyclophosphamide (All Patients)
    1. No Instruction available.
Header
Are data amended
Assessment of Chemotherapy
Total Number of Cycles Given (Docetaxel/Gemcitabine)
Why did treatment end or not begin (Docetaxel/Gemcitabine)

Similar models